| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Cryptochlorogenic acid targets oxidative stress pathways. It has antioxidative activity, including superoxide anion radical scavenging activity. It also functions as a hepatoprotective agent. As a polyphenol, it likely modulates various signaling pathways involved in inflammation and cell survival, although its specific molecular targets are not fully elucidated.
|
|---|---|
| ln Vitro |
In vitro, Cryptochlorogenic acid demonstrates antioxidant activity. It exhibits superoxide anion radical scavenging activity. Its antioxidant properties are consistent with its role as a polyphenol. It is also used as a standard in analytical chemistry for the simultaneous determination of chlorogenic acid isomers.
|
| ln Vivo |
In vivo, Cryptochlorogenic acid plays a crucial role in protection against various age-related diseases. Its hepatoprotective effects suggest it may be beneficial for liver health. It is found in many plants and is believed to contribute to their health-promoting properties.
|
| Enzyme Assay |
The in vitro antioxidant assay for Cryptochlorogenic acid involves measuring its ability to scavenge free radicals, such as superoxide anion radicals or DPPH. The compound is incubated with the radical, and the decrease in absorbance is measured. Its antioxidant capacity is compared to standard antioxidants like Trolox or ascorbic acid.
|
| Cell Assay |
In vitro cell culture studies for Cryptochlorogenic acid are limited. Its hepatoprotective effects could be studied in liver cell lines by treating cells with a hepatotoxic agent and measuring the protective effect of the compound. Its antioxidant effects could be studied by measuring its ability to reduce ROS levels in cells.
|
| Animal Protocol |
In vivo animal experiments for Cryptochlorogenic acid are not extensively documented. Its hepatoprotective effects could be studied in animal models of liver injury. Its antioxidant effects could be studied in models of oxidative stress. Its role in protecting against age-related diseases could be studied in longevity studies.
|
| ADME/Pharmacokinetics |
Cryptochlorogenic acid has a molecular formula of C16H18O9 and a molecular weight of 354.31 g/mol. It is a solid compound that is soluble in organic solvents like DMSO. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cryptochlorogenic acid are limited, as it is a research compound. As a natural polyphenol, it is generally considered to have low toxicity. However, as a research compound, it is not intended for human therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References |
|
| Additional Infomation |
4-O-trans-caffeoylquinic acid is a cinnamic ester formed by the condensation of the carboxyl group of trans-caffeic acid with the 4-hydroxyl group of (+)-quinic acid. It is a metabolite and a hepatoprotective agent. It is a cinnamic ester and a cyclic alcohol carboxylic acid. Its function is related to that of (+)-quinic acid and trans-caffeic acid. Cryptochlorogenic acid has been reported in Erigeron breviscapus, Hypericum perforatum, and other organisms with relevant data. See also: Cryptochlorogenic acid (note moved to).
Cryptochlorogenic acid is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of polyphenols and their potential applications in oxidative stress and liver diseases. It is also used as a reference standard in analytical chemistry for the quality control of herbal products. |
| Molecular Formula |
C₁₆H₁₈O₉
|
|---|---|
| Molecular Weight |
354.31
|
| Exact Mass |
354.095
|
| CAS # |
905-99-7
|
| PubChem CID |
9798666
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
694.9±55.0 °C at 760 mmHg
|
| Flash Point |
256.8±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.690
|
| LogP |
-0.97
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@H](C([C@@H](CC1(C(=O)O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O
|
| InChi Key |
GYFFKZTYYAFCTR-JUHZACGLSA-N
|
| InChi Code |
InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(21)25-14-11(19)6-16(24,15(22)23)7-12(14)20/h1-5,11-12,14,17-20,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1
|
| Chemical Name |
(1α,3R,4α,5R)-4-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-1,3,5-trihydroxy-cyclohexanecarboxylic acid
|
| Synonyms |
4-Caffeoylquinic acid Cryptochlorogenic acid 4-O-Caffeoylquinic Acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~141.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.06 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8224 mL | 14.1119 mL | 28.2239 mL | |
| 5 mM | 0.5645 mL | 2.8224 mL | 5.6448 mL | |
| 10 mM | 0.2822 mL | 1.4112 mL | 2.8224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
